SEI Investments’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

SEI Investments’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,076	Closed	-$56.4K	–	2799
2024 Q2	$56.4K	Sell	10,076 -58	-0.6%	-$253	﹤0.01%	2578
2024 Q1	$53.1K	Sell	10,134 -51,440	-84%	-$282K	﹤0.01%	2566
2023 Q4	$322K	Hold	61,574	–	–	﹤0.01%	2281
2023 Q3	$971K	Sell	61,574 -8,438	-12%	-$152K	﹤0.01%	1892
2023 Q2	$1.36M	Hold	70,012	–	–	﹤0.01%	1769
2023 Q1	$1.99M	Sell	70,012 -3,106	-4%	-$92.2K	﹤0.01%	1627
2022 Q4	$2.14M	Sell	73,118 -1,390	-2%	-$44.2K	﹤0.01%	1468
2022 Q3	$1.97M	Buy	74,508 +34,494	+86%	+$1.27M	﹤0.01%	1551
2022 Q2	$1.78M	Buy	40,014 +17,593	+78%	+$808K	﹤0.01%	1613
2022 Q1	$1.11M	Buy	22,421 +17,327	+340%	+$832K	﹤0.01%	1779
2021 Q4	$259K	Sell	5,094 -1,397	-22%	-$72.4K	﹤0.01%	2385
2021 Q3	$347K	Buy	+6,491	New	+$319K	﹤0.01%	2254
2020 Q4	–	Sell	-8,264	Closed	-$323K	–	2549
2020 Q3	$323K	Buy	8,264 +1,780	+27%	+$77.9K	﹤0.01%	2072
2020 Q2	$311K	Sell	6,484 -571	-8%	-$28.5K	﹤0.01%	2073
2020 Q1	$325K	Sell	7,055 -5,107	-42%	-$256K	﹤0.01%	1894
2019 Q4	$731K	Sell	12,162 -1,274	-9%	-$76K	﹤0.01%	1766
2019 Q3	$760K	Buy	13,436 +2,230	+20%	+$125K	﹤0.01%	1709
2019 Q2	$624K	Buy	11,206 +9,985	+818%	+$521K	﹤0.01%	1772
2019 Q1	$62K	Sell	1,221 -116,581	-99%	-$5.19M	﹤0.01%	2586
2018 Q4	$8.17M	Hold	117,802	–	–	0.03%	648
2018 Q3	$8.17M	Buy	117,802 +5,523	+5%	+$419K	0.03%	629
2018 Q2	$8.49M	Buy	112,279 +78,953	+237%	+$4.97M	0.03%	654
2018 Q1	$1.76M	Buy	33,326 +460	+1%	+$26.7K	0.01%	1255
2017 Q4	$1.76M	Buy	32,866 +6,048	+23%	+$337K	0.01%	1334
2017 Q3	$1.6M	Buy	26,818 +5,357	+25%	+$324K	0.01%	1292
2017 Q2	$1.69M	Sell	21,461 -974	-4%	-$79.7K	0.01%	1259
2017 Q1	$1.86M	Buy	22,435 +17,005	+313%	+$1.26M	0.01%	1184
2016 Q4	$431K	Buy	+5,430	New	+$394K	﹤0.01%	1620
2016 Q1	–	Sell	-6,080	Closed	-$539K	–	2669
2015 Q4	$539K	Buy	+6,080	New	+$480K	﹤0.01%	1329

Other funds holding EGRX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SEI Investments's EGRX Position: Q3 2024 in Review

SEI Investments sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 10,076 shares — an estimated $56.4K sold.

SEI Investments first reported a position in EGRX in Q4 2015 and held it in 29 quarters. The position peaked at $8.49M in Q2 2018. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

SEI Investments reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
SEI Investments sold 10,076 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $56.4K.
SEI Investments first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 29 quarters.
SEI Investments's Eagle Pharmaceuticals, Inc. position peaked at $8.49M in Q2 2018.
65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on SEI Investments's 13F filing for Q3 2024, filed 12 Nov 2024.